TKNO

Alpha Teknova NASDAQ: TKNO raised its 2026 revenue guidance after reporting a second consecutive quarter of record revenue, as demand for custom products from biopharma, life science tools and diagnostics customers helped drive 22% year-over-year growth.

Third quarter 2026 total revenue was $12.7 million, up 22% over the same quarter prior year Company raises 2026 revenue guidance to $46-48 million Strengthened balance sheet with $46 million public equity offering completed in October 2026 HOLLISTER, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the third quarter ended September 30, 2026.

Alpha Teknova (TKNO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

HOLLISTER, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced the pricing of its underwritten public offering of 8,000,000 shares of its common stock at a price to the public of $5.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be $40 million. Teknova has also granted the underwriters a 30-day option to purchase up to 1,200,000 additional shares of its common stock. All of the shares of common stock in the offering are to be sold by Teknova. The offering is expected to close on or about October 22, 2026, subject to the satisfaction of customary closing conditions.

HOLLISTER, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that it has commenced an underwritten public offering of its common stock. Teknova also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of shares of its common stock offered in the offering. All of the shares of common stock to be sold in the proposed offering are to be sold by Teknova. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering.

HOLLISTER, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced in conjunction with its filing of a preliminary prospectus supplement, preliminary unaudited financial results for the three months ended September 30, 2026.

Teknova and Pluristyx announce a Type II FDA Drug Master File for the PluriFreeze™ cryopreservation system, now available to developers for cross-reference

Alpha Teknova (TKNO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Alpha Teknova (TKNO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Teknova's Fill-Tek™ Dispensing System fills single-use bag orders across multiple sizes and quantities as a single lot, with no added turnaround time.